The Lancet. Infectious diseases
Immunogenicity and safety of a group B Streptococcus vaccine (GBS-AlpN) in pregnant women and their infants: a phase 2, multicentre, observer-blind, randomised, placebo-controlled study.
Paul T Heath, Ntokozo Zuma-Gwala, Rikke Bek Helmig, Elizea Horne, Anette Kjærbye-Thygesen, Mie Korslund Wiinblad Crusell, Maphoshane Nchabeleng, Renate Strehlau, Mohammed R Khalil, Christine E Jones, Jorne Biccler, Jeannett Dimsits, Bengt Johannsson-Lindbom, Lidia Oostvogels, Shabir A Madhi
Published: 202510.1016/S1473-3099(25)00659-0
Abstract
BACKGROUND: GBS-AlpN is a novel group B streptococcus maternal vaccine, based on the N-terminal domains of the alpha-like proteins AlphaCN, RibN, Alp1N, and Alp2/3N, which are responsible for 99% of invasive group B streptococcus strains. We aimed to…
Preview only. Read the full abstract at the source